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Cromolyn Sodium for
Insulin-Induced
Lipoatrophy: Old
Drug, New Use
L
ocal insulin-induced lipoatrophy,
an immune-mediated loss of sub-
cutaneous adipose tissue at insulin
administration sites, is now a rare com-
plication of insulin therapy in patients
with diabetes. Lipoatrophy incidence,
previously noted in 10–55% of patients
using animal-derived insulins (1), de-
clined considerably with the advent of
and improved purity of modern insulins.
Yet, it continues to be reported with in-
sulin analogs (2,3) and poses a clinical
challenge owing to erratic insulin absorp-
tion at affected areas and distressing cos-
metic issues.
Wepreviouslydemonstratedincreased
degranulating tryptase/chymase-positive
mastcellsinbiopsies frominsulin-induced
lipoatrophic sites and reported that topi-
cal cromolyn sodium (prepared with 4%
cromolyn sodium in petrolatum solvent
for topical administration twice daily to
affected areas) was efﬁcacious therapy in a
small series (4). Since this report, we were
contacted by 34 health care providers,
caregivers, and patients worldwide, to
whom we administered surveys to stan-
dardize evaluation of their treatment
experiences. The study was approved by
the institutional review board of the Joslin
Diabetes Center.
Twenty-one responded, providing
data on 24 patients with insulin-induced
lipoatrophy. Ten patients used cromolyn,
while the remaining attempted other
therapeutic interventions or observation
(Table 1). Ten respondents reported a
trial of cromolyn administration. Of the
10 cromolyn users, all had type 1 diabe-
tes and 70% were male, with mean age
16.1 6 5.0 years, age of diabetes diagno-
sis 6.1 6 4.4 years, age when lipoatrophy
was ﬁrst noticed 12.2 6 6.4 years, dura-
tion of insulin use prior to onset of lipoat-
rophy 6.1 6 5.2 years, and duration of
lipoatrophy 3.9 6 3.4 years. Three pa-
tients had Hashimoto thyroiditis and
one other had hyperthyroidism as associ-
ated autoimmune diseases.
Insulin preparations associated with
lipoatrophy included aspart (n 5 4),
lispro (n 5 5), regular human insulin
(n 5 1), NPH insulin (n 5 1), glargine
(n 5 2), and detemir (n 5 1), with three
patients reporting use of more than one
insulin preparation. Lipoatrophy oc-
curred in regions corresponding to com-
mon insulin injection sites: abdomen
(n 5 6), thighs (n 5 5), and buttocks
(n 5 3), with sizes ranging from 2 3 2
cm to 8 3 10 cm. Eight patients reported
multiple lipoatrophic sites.
Among the 10 cromolyn users, 3 ini-
tially attempted to treat lipoatrophy by
switching insulins, while 2 changed from
injections to continuous subcutaneous
insulin infusion without improvement.
All patients who used cromolyn found it
to be at least partially effective; six re-
ported complete resolution of lipoatro-
phic sites, while four reported partial
resolution. These improvements were
attributed to cromolyn use by the health
care providers or patients. The mean time
from initiating cromolyn to noticeable
clinical response was 3.1 6 0.9 months.
No side effects or adverse events were re-
ported in association with cromolyn.
Switching insulins and cromolyn
were the most frequent therapeutic inter-
ventions for lipoatrophy in this series.
Cromolyn was reported to be more
successful in enabling complete resolution
of lipoatrophy than other interventions.
To our knowledge, this is the largest
caseseriestodateofpatientswithinsulin-
induced lipoatrophy. The retrospective
study design, patient/provider qualitative
response, and use of multiple interven-
tionsforlipoatrophyinnoncromolynusers
could have restricted the interpretation
of results. Nonetheless, topical cromolyn
sodium appears to be a well-tolerated and
effective option for managing insulin-
induced lipoatrophy.
ENG-JOO PHUA, MBBS
1,2
XIMENA LOPEZ, MD
3
JULIA RAMUS, RN
1
ALLISON B. GOLDFINE, MD
1,2
From the
1Joslin Diabetes Center, Boston, Massachu-
setts; the
2Harvard Medical School, Boston, Massa-
chusetts; and the
3Department of Pediatrics,
University of Texas Southwestern, Dallas, Texas.
Corresponding author: Allison B. Goldﬁne, allison.
goldﬁne@joslin.harvard.edu.
DOI: 10.2337/dc13-1123
© 2013 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
proﬁt, and the work is not altered. See http://
creativecommons.org/licenses/by-nc-nd/3.0/ for
details.
Acknowledgments—This work was sup-
ported by grant P30DK036836 from the
National Institutes of Health. E.-J.P. received
fellowship funding as part of the Health
Manpower Development Plan award from
Alexandra Health Pte. Ltd. (Singapore).
No potential conﬂicts of interest relevant to
this article were reported.
E.-J.P.researcheddata,performedstatistical
analysis, contributed to the discussion, and
wrote and edited the manuscript. X.L. and J.R.
researcheddata,contributedtothediscussion,
and reviewedthe manuscript. A.B.G. designed
the study, researched data, contributed to the
discussion, and reviewed and edited the
manuscript. A.B.G. is the guarantor of this
work and, as such, had full access to all of the
data in the study and takes responsibility for
theintegrityofthedataandtheaccuracyofthe
data analysis.
The authors thank the health care providers,
caregivers, and patients who shared their expe-
rience by participating in the study survey.
cccccccccccccccccccccccc
References
1. Reeves WG, Allen BR, Tattersall RB. Insulin-
induced lipoatrophy: evidence for an
immune pathogenesis. BMJ 1980;280:
1500–1503
2. Holstein A,Stege H, Kovacs P. Lipoatrophy
associatedwiththeuseofinsulinanalogues:
Table 1—Therapeutic interventions for insulin-induced lipoatrophy
Intervention Patients
Complete
resolution Partial resolution No change
Topical cromolyn sodium 10 6 4 0
Noncromolyn users*
Changed insulin preparation 10 2 6 2
Continuous subcutaneous
insulin infusion 4 2 0 2
Glucocorticoid use 2 1 0 1
Spontaneous resolution 1 1 0 0
Data are n. *Noncromolyn users exceed 14 cases, as patients may have used more than one treatment option.
e204 DIABETES CARE, VOLUME 36, DECEMBER 2013 care.diabetesjournals.org
ONLINE LETTERSa new case associated with the use of insulin
glargine and review of the literature. Expert
Opin Drug Saf 2010;9:225–231
3. Babiker A, Datta V. Lipoatrophy with insu-
lin analogues in type I diabetes. Arch Dis
Child 2011;96:101–102
4. LopezX,CastellsM,RickerA,VelazquezEF,Mun
E, Goldﬁne AB. Human insulin analog–induced
lipoatrophy. Diabetes Care 2008;31:442–444
care.diabetesjournals.org DIABETES CARE, VOLUME 36, DECEMBER 2013 e205
Online Letters